Sphingosine-1-phosphate receptor 1 modulator
Ponesimod
Brand names: Ponvory
Adult dose
Dose: Day 1–14 dose-titration pack from 2mg OD up to 20mg OD
Route: PO
Frequency: OD
Clinical pearls
- Active relapsing MS
- Pre-treatment ECG, ophthalmic, VZV, LFTs; first-dose monitoring
Contraindications
- Recent (≤6mo) MI/stroke/severe HF
- Mobitz II or higher AV block without pacemaker
- Severe untreated sleep apnoea
- Pregnancy
Side effects
- First-dose bradycardia/AV block
- Hepatotoxicity
- Macular oedema
- Infections
- Reduced FEV1
Interactions
- β-blockers
- Antiarrhythmics
- Live vaccines
Monitoring
- LFTs
- FBC
- BP
- Ophthalmic
- ECG
Reference: BNF; NICE TA767; SmPC; https://bnf.nice.org.uk/drugs/ponesimod/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS